MX356279B - Métodos para el tratamiento de soriasis usando antagonistas de il-17. - Google Patents

Métodos para el tratamiento de soriasis usando antagonistas de il-17.

Info

Publication number
MX356279B
MX356279B MX2013003916A MX2013003916A MX356279B MX 356279 B MX356279 B MX 356279B MX 2013003916 A MX2013003916 A MX 2013003916A MX 2013003916 A MX2013003916 A MX 2013003916A MX 356279 B MX356279 B MX 356279B
Authority
MX
Mexico
Prior art keywords
treating psoriasis
antagonists
methods
antibody
binding molecule
Prior art date
Application number
MX2013003916A
Other languages
English (en)
Spanish (es)
Other versions
MX2013003916A (es
Inventor
Guettner Achim
Machacek Matthias
Papavassilis Charis
Sander Oliver
Original Assignee
Novartis Ag Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44759699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX356279(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag Star filed Critical Novartis Ag Star
Publication of MX2013003916A publication Critical patent/MX2013003916A/es
Publication of MX356279B publication Critical patent/MX356279B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2013003916A 2010-10-08 2011-10-07 Métodos para el tratamiento de soriasis usando antagonistas de il-17. MX356279B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39138810P 2010-10-08 2010-10-08
PCT/EP2011/067522 WO2012045848A1 (en) 2010-10-08 2011-10-07 Methods of treating psoriasis using il-17 antagonists

Publications (2)

Publication Number Publication Date
MX2013003916A MX2013003916A (es) 2013-06-03
MX356279B true MX356279B (es) 2018-05-22

Family

ID=44759699

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003916A MX356279B (es) 2010-10-08 2011-10-07 Métodos para el tratamiento de soriasis usando antagonistas de il-17.

Country Status (28)

Country Link
US (9) US9717791B2 (enExample)
EP (5) EP2625199B1 (enExample)
JP (2) JP5537740B2 (enExample)
KR (3) KR20130110179A (enExample)
CN (2) CN103154031A (enExample)
AU (1) AU2011311482B2 (enExample)
BR (1) BR112013008501A2 (enExample)
CA (1) CA2813900C (enExample)
CL (1) CL2013000930A1 (enExample)
CY (1) CY1119942T1 (enExample)
DK (1) DK2625199T3 (enExample)
ES (1) ES2660770T3 (enExample)
HK (1) HK1247932A1 (enExample)
HR (1) HRP20180301T1 (enExample)
HU (1) HUE038334T2 (enExample)
IL (1) IL225310A (enExample)
LT (1) LT2625199T (enExample)
MA (1) MA34646B1 (enExample)
MX (1) MX356279B (enExample)
NO (1) NO2625199T3 (enExample)
PH (1) PH12013500660B1 (enExample)
PL (1) PL2625199T3 (enExample)
PT (1) PT2625199T (enExample)
RU (2) RU2591083C2 (enExample)
SG (1) SG188979A1 (enExample)
SI (1) SI2625199T1 (enExample)
TW (2) TWI548419B (enExample)
WO (1) WO2012045848A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
IN2012DN06720A (enExample) 2010-01-15 2015-10-23 Kirin Amgen Inc
KR20130080790A (ko) 2010-05-20 2013-07-15 아블린쓰 엔.브이. Ｈｅｒ３와 관련된 생물학적 물질들
SI3757126T1 (sl) 2010-11-05 2025-12-31 Novartis Ag Postopki za zdravljenje psoriatičnega artritisa z antagonisti il-17
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
RU2014125071A (ru) * 2011-11-21 2015-12-27 Новартис Аг Способы лечения псориатического артрита (psa) с использованием антагонистов il-17 и аллелей ответа psa или отсутствия ответа psa
EP2968488A1 (en) * 2013-03-15 2016-01-20 Amgen Inc. Methods for treating psoriasis using an anti-il-23 antibody
NZ712294A (en) * 2013-03-15 2020-04-24 Amgen Inc Methods for treating crohn’s disease using an anti-il23 antibody
EP3033107A1 (en) * 2013-08-15 2016-06-22 Novartis AG Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
CA2935046C (en) * 2013-12-27 2021-04-13 Osaka University Vaccine targeting il-17a
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
JP6596014B2 (ja) * 2014-03-31 2019-10-23 アムジェン ケー・エー，インコーポレイテッド 爪および頭皮乾癬の治療方法
JP2017521479A (ja) 2014-05-15 2017-08-03 ラニ セラピューティクス， エルエルシー ポリペプチドおよび／またはタンパク質を含む固体塊の薬学的組成物およびそれを製造するための方法
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
SG11201701276SA (en) * 2014-08-26 2017-03-30 Kirin Amgen Inc Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
JP2017528465A (ja) * 2014-09-10 2017-09-28 ノバルティス アーゲー 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ−１７アンタゴニストの使用
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
US10500273B2 (en) 2015-03-02 2019-12-10 180 Therapeutics Lp Method of treating a localized fibrotic disorder using an IL-33 antagonist
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
JP6931648B2 (ja) * 2015-10-27 2021-09-08 ユーシービー バイオファルマ エスアールエル 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法
US20190194311A1 (en) 2016-07-19 2019-06-27 Novartis Ag Methods of treating new-onset plaque type psoriasis using il-17 antagonists
WO2018096467A1 (en) * 2016-11-28 2018-05-31 Novartis Ag Methods of treating acne using interleukin-17 (il-17) antagonists
WO2018158741A1 (en) * 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
CN111032691A (zh) * 2017-08-23 2020-04-17 伊莱利利公司 生殖器银屑病的治疗
TWI725532B (zh) * 2018-09-11 2021-04-21 美商美國禮來大藥廠 治療牛皮癬之方法
US20220267432A1 (en) 2019-07-30 2022-08-25 Jiangsu Hengrui Medicine Co., Ltd. Method for treating autoimmune disease by il-17 antagonist
CN114981302A (zh) 2019-09-20 2022-08-30 诺华股份有限公司 使用白细胞介素-17(il-17)拮抗剂治疗自身免疫性疾病的方法
WO2022127842A1 (zh) * 2020-12-17 2022-06-23 上海华奥泰生物药业股份有限公司 靶向il-17a和il-36r的双特异性抗体及其应用
WO2022184114A1 (zh) * 2021-03-03 2022-09-09 苏州盛迪亚生物医药有限公司 抗il-17抗体治疗自身免疫性疾病和炎症的方法
WO2023186174A1 (en) * 2022-04-01 2023-10-05 Zai Lab (Shanghai) Co., Ltd. Topical formulation comprising an il-17a binding molecule and uses thereof
CN116593718B (zh) * 2023-07-18 2023-09-15 军科正源（北京）药物研究有限责任公司 用于检测司库奇尤单抗抗药性抗体的试剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
US6093745A (en) * 1997-11-25 2000-07-25 Psorx, L.L.C. Methods and composition for treating skin proliferative diseases
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
TWI439284B (zh) * 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
CN101296706B (zh) * 2005-09-01 2011-11-30 先灵公司 Il-23和il-17拮抗剂治疗自身免疫性眼部炎性疾病的用途
PL1963368T6 (pl) * 2005-12-13 2021-02-08 Eli Lilly And Company Przeciwciała anty-IL-17
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
RU2367429C2 (ru) 2007-01-30 2009-09-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ лечения псориаза
WO2008150490A2 (en) * 2007-06-01 2008-12-11 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriasis and crohn's disease
RU2341272C1 (ru) 2007-10-22 2008-12-20 Левон Никитович Мкртчян Средство для неспецифической иммунотерапии
JP5581323B2 (ja) 2008-09-29 2014-08-27 ロシュ グリクアート アクチェンゲゼルシャフト ヒトｉｌ１７に対する抗体およびその使用

Also Published As

Publication number Publication date
US11534490B2 (en) 2022-12-27
EP4137514A1 (en) 2023-02-22
EP2625199A1 (en) 2013-08-14
US9717791B2 (en) 2017-08-01
US20250161443A1 (en) 2025-05-22
US20200171147A1 (en) 2020-06-04
RU2591083C2 (ru) 2016-07-10
CN107029234A (zh) 2017-08-11
EP3299390A1 (en) 2018-03-28
IL225310A0 (en) 2013-06-27
KR20150018595A (ko) 2015-02-23
BR112013008501A2 (pt) 2016-08-16
JP2014114288A (ja) 2014-06-26
CA2813900A1 (en) 2012-04-12
EP3792281A1 (en) 2021-03-17
TW201216984A (en) 2012-05-01
PH12013500660A1 (en) 2013-05-20
NO2625199T3 (enExample) 2018-04-21
US20170304439A1 (en) 2017-10-26
CY1119942T1 (el) 2018-12-12
HK1247932A1 (en) 2018-10-05
CN103154031A (zh) 2013-06-12
TW201630625A (zh) 2016-09-01
MX2013003916A (es) 2013-06-03
RU2013120957A (ru) 2014-11-20
PH12013500660B1 (en) 2017-10-27
AU2011311482B2 (en) 2014-05-29
HUE038334T2 (hu) 2018-10-29
KR101620771B1 (ko) 2016-05-12
PL2625199T3 (pl) 2018-04-30
CA2813900C (en) 2017-01-10
LT2625199T (lt) 2018-03-12
US20230321231A1 (en) 2023-10-12
US20250161445A1 (en) 2025-05-22
KR20130110179A (ko) 2013-10-08
US20250161444A1 (en) 2025-05-22
US20210162044A1 (en) 2021-06-03
US20130202610A1 (en) 2013-08-08
SG188979A1 (en) 2013-05-31
MA34646B1 (fr) 2013-11-02
EP2625199B1 (en) 2017-11-22
JP5537740B2 (ja) 2014-07-02
CL2013000930A1 (es) 2014-03-28
DK2625199T3 (en) 2018-02-26
KR20140097566A (ko) 2014-08-06
US20210113688A1 (en) 2021-04-22
IL225310A (en) 2016-10-31
ES2660770T3 (es) 2018-03-26
TWI548419B (zh) 2016-09-11
EP4670788A2 (en) 2025-12-31
AU2011311482A1 (en) 2013-04-04
SI2625199T1 (en) 2018-03-30
TWI564022B (zh) 2017-01-01
HRP20180301T1 (hr) 2018-03-23
JP2013543501A (ja) 2013-12-05
RU2665954C1 (ru) 2018-09-05
WO2012045848A1 (en) 2012-04-12
US10583190B2 (en) 2020-03-10
PT2625199T (pt) 2018-02-28

Similar Documents

Publication Publication Date Title
PH12013500660B1 (en) Methods of treating psoriasis using il-17 antagonists
PH12013500890A1 (en) Methods of treating rheumatoid arthritis using il-17 antagonists
CY1122278T1 (el) Αντι il-36r αντισωματα
PH12016500141A1 (en) Methods of treating sporadic inclusion body myositis
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
PH12013500315A1 (en) Antibodies that bind myostatin, compositions and methods
EA201300256A1 (ru) Антитела к рецептору эпидермального фактора роста-3 (her3)
MX2012003598A (es) Anticuerpos biespecificos agonistas de receptores de muerte.
MX343858B (es) Anticuerpos anti-il-23.
EA201391332A1 (ru) Лиганды опиоидных рецепторов и способы их применения и получения
WO2012103360A3 (en) Wnt compositions and methods of use thereof
PH12014502406B1 (en) Anti-il-23p19 antibodies
UA106529C2 (uk) Гуманізоване антитіло до cxcr4 для лікування раку
UA107596C2 (uk) Виділений поліпептид, який зв'язується з рецептором інсуліноподібного фактора росту 1
PH12012502300A1 (en) Nicotinic receptor non-competitive antagonists
EA201390327A1 (ru) Гетероциклильные соединения в качестве лигандов гистаминовых hрецепторов
TN2013000145A1 (en) Methods of treating psoriasis using il-17 antagonists
WO2012158493A3 (en) Compounds that bind to the erythropoietin receptor
TN2013000144A1 (en) Methods of treating rheumatoid arthuritis using il-17 antagonists
PH12014500934A1 (en) Nicotinic receptor non-competitive modulators
PH12013501453A1 (en) Nicotinic receptor non-competitive antagonists
TN2013000040A1 (en) Antibodies for epidermal growth factor receptor 3 (her3)
TN2013000186A1 (en) Anti-il-23 antibodies
NZ768582A (en) Antibodies and uses thereof to detect folate receptor 1
TN2013000064A1 (en) Antibodies that bind myostatin, compositions and methods

Legal Events

Date Code Title Description
FG Grant or registration